Categories Analysis, Industrials, U.S. Markets News

What are GE’s priorities for 2019?

General Electric’s (GE) shares were down 7.5% in mid-day trade on Wednesday, a day after J.P. Morgan analyst Stephen Tusa said his price target of $6 was looking generous, following GE’s gloomy forecast for this year.

At the J.P. Morgan conference on Tuesday, GE CEO Lawrence Culp Jr. indicated that the company’s industrial free cash flow will be negative in 2019.

GE strategic priorities for 2019
(Image Courtesy: GE Power)

At the conference, GE laid out its priorities for 2019. The topmost is to improve its financial position. The company’s decision to sell its biopharma business to Danaher for $21 billion is part of these efforts. GE also reduced its dividend and is undertaking industrial dispositions worth $20 billion. The firm aims to prioritize cash generation in every business.

The second priority is to strengthen its businesses, starting with Power. The business has been facing non-operational headwinds along with execution challenges in terms of project underwriting and cost over-runs. GE plans to take additional actions in 2019 to right-size Power’s footprint.

Also read: GE’s stock soars around 15% on news of Biopharma business sale to Danaher

GE’s initial thoughts for 2019 include an expectation for organic revenue growth in the low to mid-single digit range, and strong performance in Aviation and Renewables. The company expects organic growth in the low to mid-single digit range in Healthcare. Power is expected to be down in a flat to slightly down market.

GE is expected to provide an outlook on March 14, 2019 and the stock is likely to experience some volatility at that time.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips.

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top